DEFA14A - Entrada Therapeutics, Inc. (0001689375) (Filer)

8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)

SCHEDULE 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

10-Q - Entrada Therapeutics, Inc. (0001689375) (Filer)

8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)

8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)

DEFA14A - Entrada Therapeutics, Inc. (0001689375) (Filer)

DEF 14A - Entrada Therapeutics, Inc. (0001689375) (Filer)

S-8 - Entrada Therapeutics, Inc. (0001689375) (Filer)

8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units ("RSUs") to six newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the "Inducement Plan"), effective as of June 1, 2025. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest quart

– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation (EU-CTR) to initiate ELEVATE-45-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-45 in patients living with Duchenne muscular dystrophy (DMD) who are amenable to exon 45 skipping. "ELEVATE-45-201 is the most advanced clinical

– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 and ELEVATE-45-201 in Q2 and Q3 2025, respectively – – Cash runway expected into Q2 2027 with $383 million in cash, cash equivalents and marketable securities as of March 31, 2025 – BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today reported financial results for the first quarter ended March 31, 2025, and highlighted recent business updates. "We are excited to announce the first European Union r

– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing –  – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced it has received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1/2 multiple ascending dose (MAD) clinical study to evaluate Entrada's investigational medicina

– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in cash, cash equivalents and marketable securities as of December 31, 2024 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today reported financial results for the fourth quarter and full year ended December 31, 2024 and highlighted recent business updates. "We are thrilled to begin 2025 with significant mome

– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initi

– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced it had received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mu

BURLINGTON, Mass., Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA) and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier today.  Mr. Doshi was nominated for election by the Board, together with nine returning directors, in December 2024. "Mr. Doshi is an extraordinary leader who brings significant experience in the biotechnology and pharmaceutical industries," said John Marotta, President and CEO of Azenta. "His experience in strategy, operational and commercial growth, and

BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET). A live webcast will be available on the Presentations portion of Entrada's Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event.

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)

SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)

SC 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada

āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,

BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. "Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Wit

- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 -- Cash runway into the second half of 2025 - BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent business updates. "In the first quarter, we successfully closed on our transformational collaboration with Vertex for the development of EEV-therapeutics targeting myotonic dystrophy type 1, the most prev

BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Dr. Bernhardt "Bernie" Zeiher to its Board of Directors, effective immediately. Dr. Zeiher served most recently as the Chief Medical Officer at Astellas Pharma. "Bernie is a dynamic life sciences leader and we look forward to having him join our Board of Directors," said Dipal Doshi, President and Chief Executive Officer of Entrada. "As the former Chief Medical Officer and President of Development at

BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced the appointment of Karla MacDonald as Chief Corporate Affairs Officer, effective immediately. Ms. MacDonald previously served as Entrada's Vice President of Corporate Communications and Investor Relations. She remains a member of the Entrada executive team and will report to Dipal Doshi, Entrada's President and Chief Executive Officer. "Karla is a transformational leader who has already demonstrated her value as a membe

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately. "We are thrilled to recognize the appointment of Jared to General Counsel," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Since joining Entrada, Jared has been critical in leading our legal and compliance functions, guiding us through our recent financings and building a robust patent estate covering

ROTH MKM initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $29.00

Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $22.00

H.C. Wainwright initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $25.00

Evercore ISI Group initiated coverage of Entrada Therapeutics with a rating of Outperform

Cowen & Co. initiated coverage of Entrada Therapeutics with a rating of Outperform

Goldman Sachs initiated coverage of Entrada Therapeutics with a rating of Neutral and set a new price target of $29.00